Pharmacokinetics of oral tacrolimus in recipients of allogeneic hematopoietic stem cell transplantation  by Yamazaki, R. et al.
195
PHARMACOKINETICS OF ORAL TACROLIMUS IN RECIPIENTS OF ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Yamazaki, R., Mori, T., Nakazato, T., Aisa, Y., Ikeda, Y., Okamoto, S.
Division of Hematology, Department of Medicine, Keio University School
of Medicine, Tokyo, Japan.
Background: Tacrolimus is an immunosuppressive agent used
for the prevention and treatment of graft-versus-host-disease
(GVHD) in allogeneic hematopoietic stem cell transplantation
(HSCT). In contract to its intravenous formulation, pharmacoki-
netics of oral administered tacrolimus was yet to be fully examined.
Patients /Methods: Recipients of allogeneic HSCT with GVHD
prophylaxis using tacrolimus were eligible. Tacrolimus were initi-
ated by continuous intravenous infusion from day 1, and contin-
ued until patients became capable of taking tacrolimus orally. On
the second day of oral tacrolimus administration, whole blood
concentration of tacrolimus was measured by MEIA before, 30min,
1, 2, 3, 4, 6, and 12 hours after administration. Results: Thirteen
patients were evaluable. Mean blood level before administration
(C0) was 9.851.85 ng/mL. Mean maximum concentration (Cmax)
was 19.812.3 ng/mL, and median Tmax was 3 hours (range; 1–6
hours). Two subgroups were identiﬁed in regard to the difference
between C0 and Cmax; Cmax  C0 10 ng/mL (Group A: n  4)
and Cmax  C0 10 ng/mL (Group B: n  9). Although there was
no signiﬁcant difference in C0 and C12 between the two groups,
mean area under the concentration curve for 12 hours (AUC0–12)
in group A was signiﬁcantly greater than that in group B (204 
51.6 vs 136  22.9 nghr/mL; P  .045). Mean half-life of tacroli-
mus in group A was signiﬁcantly shorter than that in group B
(16.2  8.28 hr vs 42.8  15.5 hour; P  .041). Discussion:
Pharmacokinetics of orally administered tacrolimus did not neces-
sarily show a uniform pattern; and a prominent feature was an
unexpectedly high Cmax and AUC observed in some patients.
However, this phenomenon could not be recognized only by mea-
suring its trough level (C0) because of alteration in its half-life. We
conclude that pharmacokinetic analysis should be performed in
every patient to decide optimal dose of tacrolimus to prevent
overdosing.
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DIFFERENTIAL EFFECTS OF IMMUNOSUPPRESSANTS ON ADOPTIVELY
TRANSFERRED CD4CD25high REGULATORY T CELLS IN PREVENTION
OF EXPERIMENTAL ACUTE GRAFT-VERSUS-HOST DISEASE
Zeiser, R.1, Nguyen, V.1, Beilhack, A.1, Schulz, S.2, Baker, J.1,
Contag, C.H.3, Negrin, R.S.1 1. Stanford University, Department of
Medicine, Stanford, CA; 2.Technische Universitat Munchen, Munchen,
Germany; 3. Stanford University, Department of Pediatrics, Stanford,
CA.
The observation that CD4CD25regulatory T cells (Treg) are
capable of suppressing experimental aGVHD while preserving the
beneﬁcial graft-versus-tumor effect (GVT), fueled interest in ex-
ploring cell-based immunotherapy in clinical trials. However, in
contrast to experimental models of aGVHD, most clinical trans-
plantation protocols include combinations of immunosuppressive
drugs and currently there is no information on the impact of these
drugs on Treg function in vivo. Therefore, we evaluated the
impact of Cyclosporine A (CSA), Mycophenolate mofetile (MMF),
and Rapamycin (RAPA) on Treg function both in vitro and in vivo
in a murine acute GVHD model. Treg reisolated from mixed
leucocyte reactions (MLR) containing CSA but not RAPA showed
signiﬁcantly reduced ability to suppress CD4CD25- T cell pro-
liferation in secondary MLRs (P  .025). The CSA effect could be
reversed to 85  3.4% by the addition of IL-2 (50 IU/ml) to the
primary culture. In vivo bioluminescence imaging (BLI) after ma-
jor mismatch BMT demonstrated reduced early proliferation of
donor derived luciferase-labeled conventional T-cells (Tcluc) in
animals treated with Treg. The addition of RAPA and to a lesser
extent MMF did not interfere with Treg function. Conversely,
combining Treg with CSA led to a signiﬁcantly increased Tcluc
proliferation (P  .002) indicating loss of Treg function. Treat-
ment with Treg/CSA was associated with increased GVHD risk
and poorest survival of the Treg/drug combinations. The Treg/
RAPA combination did not abrogate GVT effector function of
donor derived conventional T-cells against A20luc leukemia cells
as determined by BLI and histology. Our data indicate that CSA,
but not RAPA or MMF reduces Treg function possibly through an
IL-2 dependent mechanism. In vivo, the combination of Treg with
RAPA or MMF allowed for adequate GVHD suppression with
retention of GVT activity which may provide guidance for clinical
trials.
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PHARMACOKINETICS OF ANTI TUMOR NECROSIS FACTOR ANTIBODY
(INFLIXIMAB) IN CHILDREN WITH ACUTE GVHD INVOLVING THE GAS-
TROINTESTINAL TRACT
Sleight, B.1, Shenoy, S.2, Haight, A.3, Vora, R.4, Prabhakar, U.4,
Schultz, K.5, Gamis, A.6, Levine, J.7, Braun, T.7, Yanik, G.7 1. Yale
University, New Haven, CT; 2. Washington University, St. Louis, MO;
3 Emory University, Atlanta, GA; 4. Centocor, Inc., Malvern, PA; 5.
British Columbia Children’s Hospital, Vancouver, BC, Canada; 6. Chil-
dren’s Mercy Hospital, Kansas City, MO; 7. University of Michigan
Medical Center, Ann Arbor, MI.
Inﬂiximab (REMICADE®, Centocor), a chimeric anti-TNF

monoclonal antibody, has been used in the management of patients
with steroid-refractory acute GVHD. Though preliminary results
using inﬂiximab have been encouraging, the pharmacokinetics (Pk)
of inﬂiximab in this clinical setting have yet to be deﬁned. A
prospective trial examining the Pk of inﬂiximab in pediatric pa-
tients with gastrointestinal (GI) GVHD was undertaken. Five sub-
jects (median 11 yrs, range 9 mo–17 yrs) with GI GVHD were
enrolled. All subjects had histologic conﬁrmation of GVHD and
had failed 	 48 hours of corticosteroids prior to study entry.
Subjects received a single 5 mg/kg dose of inﬂiximab. PK and
pharmacodynamic samples were drawn at 16 time points (hours
0, 1, 2, 6, 24, 48, 96, weekly days 7–42, days 56, 70, 84). Based
upon existing Pk data in patients with Crohn’s disease, the time
required to reach a trough concentration 2 mcg/ml was the
deﬁned primary study endpoint. Results: Dosing was well tol-
erated in all ﬁve subjects. Inﬂiximab concentrations are as fol-
lows: Peak concentrations (Cmax) ranged from 64-160 mcg/ml
and were achieved by hours 2–6. Drug concentrations 	 20
mcg/ml were maintained for 	 7 days in all subjects. The
primary endpoint (trough concentration x 2 mcg/ml) was
reached on days 28, 35, 21, 35, and 7(asterisk) (median 28 days,
mean 25 days), respectively. Infectious complications with a
possible attribution to inﬂiximab included endocarditis on day
21 in 1 subject and CMV reactivation 1 month post inﬂiximab in
a second subject. No invasive fungal infections were seen. Du-
rable complete responses of GVHD were seen in 2 subjects by
days 7 and 28, respectively. Two subjects are alive (6 months and
16 months). Conclusion: In summary, pharmacokinetics of
inﬂiximab indicate that concentrations 	 the targeted threshold
level can be maintained for several weeks following a single 5
mg/kg dose in patients with GI GVHD. A phase II clinical trial,
with dosing intervals based upon these Pk parameters, will be
required. This investigator-initiated study was conducted
through the Pediatric Blood and Marrow Transplant Consor-
tium. Inﬂiximab and partial ﬁnancial support were provided by
Centocor, Inc.
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REDUCED-INTENSITY CONDITIONING PERMITS A SIGNIFICANT GRAFT
VS LEUKEMIA (GvL) EFFECT FOR ACUTE LEUKEMIA
Arellano, M., Flowers, C., Waller, E., Lonial, S., Kaufman, J.,
Winton, E., Khoury, H., Langston, A. Emory University, Atlanta, GA.
Delivering effective treatment for acute leukemia to older adults
remains a signiﬁcant challenge. Bone marrow/hematopoietic pro-
genitor cell transplant (HPCT) remains the only curative option
for relapsed/refractory or unfavorable risk disease. Myeloablative
conditioning regimens are associated with signiﬁcant morbidity
and mortality. The use of reduced intensity conditioning (RIC)
may offer a chance for cure, but whether RIC allows for a signif-
icant GvL effect is unclear. We report a single institution fol-
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